Hematologic neoplasms are a heterogeneous group of cancers comprising several subgroups of neoplasms. So far, despite major epidemiological concerns about quality of care, limited data are available for patients with hematologic malignancies. To retrospectively analyze the epidemiological, clinical and hematological characteristics of patients at the Hospital Universitário de Vassouras, Rio de Janeiro, Brazil during the COVID-19 pandemic. In addition, it aims to report the most prevalent hematological diseases in the municipality. In addition, it is important to consider that patients with hematological malignancy are immunocompromised. It is expected that the present study will reveal that there is an increased risk of serious events related to COVID-19 (ICU admission, need for MV or death) in patients with hematologic malignancy compared to patients infected with COVID-19 without cancer. due to the high vulnerability of patients with hematological malignancies in the current pandemic. It was observed that there is an increased risk of serious events related to COVID-19 (ICU admission, need for MV or death) in patients with hematologic malignancy compared to patients infected with COVID-19 without cancer due to the high vulnerability of the patients. patients with hematologic malignancies in the current pandemic. It was therefore noted that clinicians must pay close attention to treating COVID-19 patients with hematologic malignancy. Telephone screening or other online technologies must be used to verify the need for treatment or follow-up at inpatient or outpatient clinics. In non-lifethreatening patients, hospitalization must be postponed. Patients with fever or other symptoms that may be related to COVID-19 must be tested for SARS-CoV-2 RNA and they must not be accepted into the hematology ward before the possibility of COVID-19 has

Analgesia for burn patients is often prescribed with opioids at significantly longer and longer doses and durations than analgesic dosing guidelines suggest. However, many patients remain without pain relief. There is also a high risk of developing dependence and opioid use disorder such as hyperalgesia and tolerance. In addition, acute metabolic changes, exacerbated inflammatory cascades, and fluid changes associated with major thermal injuries create significant changes in the volume of distribution and pharmacokinetics of opioids in burn patients. Given these individual and unpredictable variables for each patient and the limited therapeutic windows of these agents, it is evident that pain and opioids require continuous assessment and adjustments for safe and effective pain control in this population, based on dose-response.

Non-Steroidal Anti-Inflammatory Drugs are frequently prescribed in medical practice, are one of the most widely used drug classes in the world and carry a low but tangible risk of causing Acute Kidney Injury, electrolyte imbalances and increased blood pressure. However, studies showing the long-term effects of NSAID use on the development of CKD are still minimal, as such studies routinely exclude people with CKD and rarely report renal outcomes. The present study aimed to report the importance of using this pharmacological class with caution. A descriptive, qualitative study of current Literature Review was carried out to prepare the work. Was the risk of ARI associated with the use of NSAIDs in patients with CKD evaluated? The Medline database (via PubMed) was used, with preference given to the most current full-text articles, such as from 2014 to 2021. Only articles in English were selected. The results of the literature review showed that current exposure to NSAIDs was associated with an approximately 1.5fold increase in the odds of developing Acute Kidney Injury in the general population and in people with Chronic Kidney Disease. This study found that the chances of developing ARI increased by more than 50% in people who were exposed to NSAIDs in the general population and in people with CKD, and in older people the chance of developing ARI doubled. Future research must quantify the level of high-dose use in patients with CKD and explore the effects of comorbidities and co-prescription.

In the first 6 months of human exposure to the Severe Acute Respiratory Syndrome that causes COVID-19, there were over 9,000,000 confirmed infections and nearly 500,000 deaths worldwide. As of November 13, 2021, it is estimated that there were over 250 million confirmed cases of COVID-19 and over 5 million deaths. From another perspective, the prevalence of obesity has recently increased in many developed and developing countries and has doubled in 73 countries since 1980. Emerging studies have also suggested that obesity is associated with worse COVID-19 outcomes, including higher rates of hospitalization and admission to the hospital. Intensive Care Unit, Invasive Mechanical Ventilation and death. However, many studies have not reproduced these findings. Therefore, it is uncertain whether obesity is indeed associated with worse COVID-19 outcomes compared to nonobese individuals. The present study aimed to clarify the relationship between obesity and the severity of COVID-19. To investigate this, we will conduct a systematic search of Web of Science, PubMed, SciELO, Scopus, and Google Scholar on December 3, 2021 to identify all published studies that report COVID-19 comorbidities or outcomes during the pandemic months. expected to find cohort studies and randomized clinical trials. Furthermore, it is expected to analyze that obese patients are more likely than non-obese patients to have severe disease, develop SARS, require hospitalization, be admitted to the ICU or require IMV. Surprisingly, however, it can be seen that obesity was not associated with an increased risk of death from COVID-19.

No abstract